BARDA Agreement	6 Months Ended
Jun. 30, 2026
Collateralized Agreements [Abstract]
BARDA Agreement	BARDA Agreement In July 2023, Melinta entered into a partnership with BARDA to advance BAXDELA and VABOMERE for use in pediatrics and to partner on the development of BAXDELA against certain biothreat pathogens (BARDA-Supported Studies). Under this contract, BARDA reimburses Melinta certain percentages of costs incurred, as defined in the agreement, in connection with the BARDA-Supported Studies. BARDA has awarded a total of $47.5 million of funding with the potential of additional funding of $97.1 million, amounting to total funding up to $144.6 million, if all options are exercised. If all contract options are exercised, the contract is expected to continue through 2034. Through June 2026, Melinta has recognized BARDA reimbursement totaling $24.4 million. Reimbursements under the BARDA agreement are recognized as grant income as qualifying costs are incurred and reflected within revenue and grant income in the accompanying condensed consolidated statements of operations. Related costs are recognized as incurred are included within operating expenses, primarily within research and development expense. The Company recognized grant income of $2.7 million and $5.1 million, respectively, under the BARDA agreement for the three and six months ended June 30, 2026.

BARDA Agreement

6 Months Ended

Jun. 30, 2026

Collateralized Agreements [Abstract]

In July 2023, Melinta entered into a partnership with BARDA to advance BAXDELA and VABOMERE for use in pediatrics and to partner on the development of BAXDELA against certain biothreat pathogens (BARDA-Supported Studies). Under this contract, BARDA reimburses Melinta certain percentages of costs incurred, as defined in the agreement, in connection with the BARDA-Supported Studies. BARDA has awarded a total of $47.5 million of funding with the potential of additional funding of $97.1 million, amounting to total funding up to $144.6 million, if all options are exercised. If all contract options are exercised, the contract is expected to continue through 2034. Through June 2026, Melinta has recognized BARDA reimbursement totaling $24.4 million.

Reimbursements under the BARDA agreement are recognized as grant income as qualifying costs are incurred and reflected within revenue and grant income in the accompanying condensed consolidated statements of operations. Related costs are recognized as incurred are included within operating expenses, primarily within research and development expense. The Company recognized grant income of $2.7 million and $5.1 million, respectively, under the BARDA agreement for the three and six months ended June 30, 2026.